News

Ionis Pharmaceuticals Q2 2025 earnings highlight strong Tryngolza sales, increased 2025 revenue guidance, and upcoming Donidalorsen FDA approval.
Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) (the "Company") today reported financial results and provided key updates for the second quarter ended June 30, 2025.
Business WireWed, Mar. 26 Ionis and Ono announce global license agreement for sapablursen in polycythemia vera Business WireTue, Mar. 11 ...